Divisions of Hematology & Oncology

• Home
• About Us
  • Overview
  • Washington U
  • St. Louis
• People
  • Faculty
  • Fellows
  • Alumni
• Conferences
  • Calendar
  • Hematology Grand Rounds
  • Medical Oncology Grand Rounds
  • Cancer Management Series
  • Clinical Trials Bootcamp
  • Fellows' Journal Club
  • Core Cases in Hematology / Oncology
  • Hematology Research / Work-In-Progress Seminar
  • Cancer Biology Pathway
• Training
  • Hematology-Oncology Fellowship
  • Hematology-Focused Fellowship Training Program
  • K12 Paul Calabresi Career Development Program in Clinical Oncology
  • T32 Training Program in Molecular Hematology
• Research
  • Basic
  • Clinical
  • Developmental Therapeutics
• Patient Care
  • Overview
  • Clinical Protocols
  • Adult Hemophilia and Bleeding Disorders Center
  • Center for Gene and Cellular Immunotherapy

Original Articles

• Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer
  Davis AA, Luo J, Zheng T, Dai C, Dong X, Tan L, Suresh R, Ademuyiwa FO, Rigden C, Rearden TP, Clifton K, Weilbaecher K, Frith A, Tandra PK, Summa T, Haas B, Thomas S, Hernandez-Aya LF, Peterson LL, Wang X, Luo SJ, Zhou K, Du P, Jia S, King BL, Krishnamurthy J, Ma CX
  Clin Cancer Res 2023 Jan 24:CCR-22-2177; [ahead of print]
• A Phase II Study of Palbociclib Plus Letrozole Plus Trastuzumab as Neoadjuvant Treatment for Clinical Stages II and III ER+ HER2+ Breast Cancer (PALTAN)
  Ademuyiwa FO, Northfelt DW, O'Connor T, Levine E, Luo J, Tao Y, Hoog J, Laury ML, Summa T, Hammerschmidt T, Guo Z, Frith A, Weilbaecher K, Opyrchal M, Aft R, Clifton K, Suresh R, Bagegni N, Hagemann IS, Iglesia MD, Ma CX
  NPJ Breast Cancer 2023 Jan 6;9(1):1
• A Phase II Trial of an Alternative Schedule of Palbociclib and Embedded Serum TK1 Analysis
  Krishnamurthy J, Luo J, Suresh R, Ademuyiwa F, Rigden C, Rearden T, Clifton K, Weilbaecher K, Frith A, Roshal A, Tandra PK, Cherian M, Summa T, Haas B, Thomas S, Hernandez-Aya L, Bergqvist M, Peterson L, Ma CX
  NPJ Breast Cancer 2022 Mar 21;8(1):35
• Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple-Negative Breast Cancer
  Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, Bose R, Bagegni N, Rigden CE, Frith A, Rearden TP, Hernandez-Aya LF, Roshal A, Clifton K, Opyrchal M, Akintola-Ogunremi O, Lee BH, Ferrando-Martinez S, Church SE, Anurag M, Ellis MJ, Gao F, Gillanders W, Griffith OL, Griffith M
  Breast Cancer Res Treat 2021 Aug;189(1):187-202
• Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma
  Van Tine BA, Hirbe AC, Oppelt P, Frith AE, Rathore R, Mitchell JD, Wan F, Berry S, Landeau M, Heberton GA, Gorcsan J 3rd, Huntjens PR, Soyama Y, Vader JM, Alvarez-Cardona JA, Zhang KW, Lenihan DJ, Krone RJ
  Clin Cancer Res 2021 Jul 15;27(14):3854-3860
• Early Assessment Window for Predicting Breast Cancer Neoadjuvant Therapy Using Biomarkers, Ultrasound, and Diffuse Optical Tomography
  Zhu Q, Ademuyiwa FO, Young C, Appleton C, Covington MF, Ma C, Sanati S, Hagemann IS, Mostafa A, Uddin KMS, Grigsby I, Frith AE, Hernandez-Aya LF, Poplack SS
  Breast Cancer Res Treat 2021 Aug;188(3):615-630
• Mutation Profile Differences in Younger and Older Patients With Advanced Breast Cancer Using Circulating Tumor DNA (CtDNA)
  Clifton K, Luo J, Tao Y, Saam J, Rich T, Roshal A, Frith A, Rigden C, Ademuyiwa F, Weilbaecher K, Hernandez-Aya L, Peterson LL, Bagegni N, Suresh R, Bose R, Opyrchal M, Wildes TM, Ma C
  Breast Cancer Res Treat 2021 Feb;185(3):639-646
• Randomized Controlled Trial of High-Dose Versus Standard-Dose Vitamin D3 for Prevention of Aromatase Inhibitor-Induced Arthralgia
  Niravath P, Hilsenbeck SG, Wang T, Jiralerspong S, Nangia J, Pavlick A, Ademuyiwa FO, Frith AE, Ma CX, Park H, Rigden CE, Suresh R, Ellis M, Kent Osborne C, Rimawi MF
  Breast Cancer Res Treat 2019 Sep;177(2):427-435
• Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
  Xi J, Oza A, Thomas S, Ademuyiwa F, Weilbaecher K, Suresh R, Bose R, Cherian M, Hernandez-Aya L, Frith A, Peterson L, Luo J, Krishnamurthy J, Ma CX
  J Natl Compr Canc Netw 2019 Feb;17(2):141-147
• Lung Cancer in Older Adults
  Frith AE, Baggstrom M
  Current Geriatrics Reports 2014 Sept;3(3):166-74
• Novel Pathways and Molecular Targets for the Treatment of Sarcoma
  Frith AE, Hirbe AC, Van Tine BA
  Curr Oncol Rep 2013 Aug;15(4):378-85
• Syndecan-1 and Heparanase Enhance VEGF Association With Endothelia
  Yang Y, Frith AE, Theus A, Macleod V, Sanderson RD
  Matrix Biology 2006 Nov; 25 (supplement 1):S60